¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"species immunity"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • adoptive immunity
    Â÷¿ë¸é¿ª, ÀÔ¾ç¸é¿ª
  • concomitant immunity
    ¼ö¹Ý¸é¿ª
  • cross immunity
    ±³Â÷¸é¿ª
  • cell-mediated immunity
    ¼¼Æ÷¸Å°³¸é¿ª
  • cellular immunity
    ¼¼Æ÷¸é¿ª
  • gut immunity
    âÀڸ鿪, Àå°ü¸é¿ª
  • herd immunity
    ¹«¸®¸é¿ª
  • humoral immunity
    ü¾×¸é¿ª
  • immunity
    1. ¸é¿ª 2. ¸é¿ª¼º
  • individual immunity
    °³Àθ鿪, °³Ã¼¸é¿ª
  • infection immunity
    °¨¿°¸é¿ª
  • innate immunity
    ¼±Ãµ¸é¿ª
  • local immunity
    ±¹¼Ò¸é¿ª
  • maternal immunity
    ¸ð¼º¸é¿ª
  • nonspecific immunity
    ºñƯÀ̸鿪
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • species-specific reactivity
    Á¾Æ¯À̹ÝÀÀ¼º
  • species
    Á¾
  • species nova
    ½ÅÁ¾
  • sibling species
    ÀÚ¸ÅÁ¾
  • species specificity
    Á¾Æ¯À̼º
  • type species
    Ç¥ÁرÕÁ¾
  • vector species
    ¸Å°³Á¾
  • acquired immunity
    ÈÄõ¸é¿ª
  • active immunity
    ´Éµ¿¸é¿ª
  • adoptive immunity
    ÀÔ¾ç¸é¿ª
  • antibody-mediated immunity
    Ç×ü¸Å°³¸é¿ª
  • antitoxic immunity
    Ç×µ¶¼Ò¸é¿ª
  • artificial active immunity
    Àΰø´Éµ¿¸é¿ª
  • athreptic immunity
    ¹«¿µ¾ç¸é¿ª
  • cell-mediated immunity
    ¼¼Æ÷¸Å°³¸é¿ª
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • antiviral immunity
    Ç×¹ÙÀÌ·¯½º¸é¿ª(¡­Øóæ¹).
  • antiviral immunity
    Ç×¹ÙÀÌ·¯½º¸é¿ª(~Øóæ¹)
  • artificial active immunity
    Àΰø´Éµ¿¸é¿ª.
  • gut immunity
    Àå°ü¸é¿ª
  • herd immunity
    ±ºÁý¸é¿ª, Áý´Ü¸é¿ª
  • herd immunity
    Áý´Ü¸é¿ª, ±ºÁý¸é¿ª, ¹«¸®¸é¿ª
  • immunity, cross
    ±³Â÷¸é¿ª
  • immunity, gut
    Àå°ü¸é¿ª
  • immunity, herd
    Áý´Ü¸é¿ª, ±ºÁý¸é¿ª, ¹«¸®¸é¿ª
  • immunity, humoral
    ü¾×¼º¸é¿ª
  • immunity, innate
    ¼±Ãµ¸é¿ª
  • immunity, local
    ±¹¼Ò¸é¿ª
  • immunity, maternal
    ¸ð¼º¸é¿ª
  • immunity, native
    ¼±Ãµ¸é¿ª
  • immunity, nonspecific
    ºñƯÀ̸鿪
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • species specific antigen
    Á¾Æ¯ÀÌÇ׿ø(ðú÷åì¶ù÷ê«).
  • species specificity
    Á¾Æ¯À̼º(ðú÷åì¶àõ).
  • species-specific reactivity
    Á¾Æ¯À̹ÝÀÀ¼º
  • type species
    Ç¥ÁرÕÁ¾(øöñÞжðú).
  • acquired immunity
    ÈÄõ¼º ¸é¿ª, ½Å°æÈ¹µæ¸é¿ª(üòÔðØóæ¹).
  • active immunity
    ´Éµ¿¸é¿ª(ÒöÔÑØóæ¹).
  • adoptive immunity
    ÀÔ¾ç¸é¿ª(¡­Øóæ¹).
  • adoptive immunity
    ÀÔ¾ç¸é¿ª(¡­Øóæ¹).
  • adoptive immunity
    ÀÔ¾ç¸é¿ª(¡­Øóæ¹).
  • antibacterial immunity
    Çױո鿪(¡­Øóæ¹).
  • antibody-mediated immunity
    Ç×ü¸Å°³ ¸é¿ª
  • antimicrobial immunity
    Çױո鿪(¡­Øóæ¹).
  • antitoxic immunity
    Ç×µ¶(¼Ò)¼º ¸é¿ª(ù÷Ô¸áÈàõØóæ¹).
  • antitumor immunity
    Ç×Á¾¾ç(¼º) ¸é¿ª(¡­Øóæ¹).
  • antiviral immunity
    Ç×¹ÙÀÌ·¯½º¸é¿ª(¡­Øóæ¹).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • protective immunity
    º¸È£ ¸é¿ª¼º(ÜÁûÞØóæ¹àõ)
  • specific immunity
    ƯÀ̸鿪(÷åì¶Øóæ¹)
  • superinfection immunity
    Áß°¨¿° ¸é¿ª (ñìÊïæøØóæ¹)
  • transferred immunity
    ÀüÀÌ ¸é¿ª (ï®ì¹Øóæ¹)
  • transplantation immunity
    ÀÌ½Ä ¸é¿ª(ì¹ãÕØóæ¹)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
HI half-scan with interpolation; head injury; health insurance; hearing impaired; heart infusion; hemag...
immun immune, immunity, immunization
IRS immunoreactive secretion; infrared spectrophotometry; insulin receptor species; insulin receptor sub...
ROS reactive oxygen species; review of systems; rod outer segment
Sp the most posterior point on the posterior contour of the sella turcica; species; specific; specimen;...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 2
TBARS Thiobarbituric acid reactive species
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • immunity deficiency
    ¸é¿ª °áÇÌ
    µ¿ÀǾî=immunodeficiency.
  • inborn immunity
    ¼±Ãµ¼º ¸é¿ª
    °³Ã¼ÀÇ À¯ÀüÀû ¼ÒÁú¿¡ ±âÀÎÇÏ´Â ¸é¿ª.
  • infection immunity
    °¨¿° ¸é¿ª
    ÀÌ¹Ì Ç׿øÀÌ °°°Å³ª °ü·ÃµÈ Ç׿øÀ» °¡Áø ¹Ì»ý¹°¿¡ ÀÇÇÑ ÁúȯÀÌ Á¸ÀçÇϱ⠶§¹®¿¡ Àç°¨¿°¿¡ ´ëÇÏ¿© ÀúÇ×·ÂÀÌ ÀÖ´Â »óÅÂ.
  • local immunity
    ±¹¼Ò ¸é¿ª
  • mucosal immunity
    Á¡¸· ¸é¿ª
  • natural active immunity
    ÀÚ¿¬ ´Éµ¿ ¸é¿ª
  • natural immunity
    ÀÚ¿¬ ¸é¿ª
  • phagocytic immunity
    ½Ä¼¼Æ÷¼º ¸é¿ª
  • racial immunity
    ¹ÎÁ· ¸é¿ª
    À¯ÀüÀûÀ¸·Î °áÁ¤µÇ¾î ÀÖ´Â ÀúÇ×¼ºÀ¸·Î, ¾î¶² Á¾Á· ¸ðµÎ ¶Ç´Â °ÅÀÇ ÀüºÎ°¡ ¾î¶² Á¾·ùÀÇ °£¿°¿¡ ´ëÇÏ¿© ³ªÅ¸³ª´Â ¸é¿ª »óÅÂ.
  • specific humoral immunity
    ƯÀ̼º ü¾× ¸é¿ª
  • transplantation immunity
    ÀÌ½Ä ¸é¿ª
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
noncommercial species Tree species that do not normally develop into suitable trees for conventional forest products because of small size, poor form, or inferior quality.
(05 Dec 1998)
dominant species <biology, ecology, zoology> For each stratum, dominant species are those that, when ranked in descending rank order and cumulatively totaled, immediately exceed 50 percent of the total dominance measure, plus any additional species comprising 20 percent or more of the total dominance measure for the stratum.
(09 Oct 1997)
intermediate species <chemistry> Species formed in a reaction consisting of more than one step. An intermediate is produced in one reaction and consumed in the following reaction.
(09 Jan 1998)
invasive species Non-native species disrupting and replacing native species.
(09 Oct 1997)
te&s species See Threatened, endangered, and sensitive species.
(05 Dec 1998)
early seral species <plant biology> Shrubs, such as ceanothus, and hardwoods, usually in tree form, such as red alder, bitter cherry and big leaf maple. These species start growing in natural succession soon after a disturbance (fire or logging).
(05 Dec 1998)
threatened, endangered, and sensitive species formal classifications of species. Sensitive
Species for which population viability is a concern. Sensitive species are not federally designated under the Endangered Species act. The U.S. Fish and Wildlife Service, after study, makes the following designations
(05 Dec 1998)
threatened species <biology, ecology, zoology> Any species which is likely to become an endangered species within the foreseeable future throughout all or a significant portion of its range.
(09 Oct 1997)
endangered species Any species which is in danger of extinction throughout all or a significant portion of its range.
(09 Oct 1997)
type species <zoology> The nominal species that is the name-bearing type of a nominal genus or subgenus.
(09 Jan 1998)
exotic species Plant or animal species introduced into an area where they do not occur naturally, non-native species.
(09 Oct 1997)
facultative species <ecology> Species that can occur both in wetlands and uplands, there are three subcategories of facultative species:
1. Facultative wetland plants (FACW) that usually occur in wetlands (estimated probability 67-99%), but occasionally are found in nonwetlands.
2. Facultative plants (FAC) that are equally likely to occur in wetlands or nonwetlands (estimated probability 34-66%).
3. Facultative upland plants (FACU) that usually occur in nonwetlands (estimated probability 67-99%), but occasionally are found in wetlands (estimated probability (1-33%).
(09 Oct 1997)
unique species <biology> A biotic resource whose presence is unusual and of special interest due to extremities of range, special soil types, or unusual associations with other species.
(09 Oct 1997)
late seral species Shade tolerant species, primarily vine maple shrubs and western red cedar and western hemlock trees. These species follow the mid seral species in natural succession.
(05 Dec 1998)
acquired immunity <immunology> A form of cellular defense which identifies certain foreign substances (antigens) as harmful to the body. For this reason, the body can acquire resistance to a particular foreign agent.
These foreign agents are then attacked by sensitised T lymphocytes (cellular immunity). White blood cells, plasma cells, B lymphocytes and other specialised immune system cells act in concert with T lymphocytes to produce antibodies (humoral immunity) that attach to the antigen directing T-cells to attack.
Antibodies also stimulate the release of special chemical mediators in the blood (for example complement, interferon) that further enhance antigen destruction.
(13 Nov 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á